Aviron

The Aviron project of ChemRar Group implements a program for the development of innovative antiviral drugs with different complementary mechanisms of action for the treatment of chronic hepatitis C, which is included in the list of socially significant diseases and known as “the silent killer”. The scientific team of the project has already completed the creation of a product line. All selected candidate drugs are best in their class, demonstrating the characteristics beyond those of the headliners of the world market leaders in preclinical and clinical studies.

AVIRUS® is an innovative combination product that inhibits the NS5A and NS5B proteins of the hepatitis C virus. Preclinical studies of AVIRUS® have shown strong antiviral activity in vitro and safety in animals. In a Phase I, double-blind, randomised, placebo-controlled study of the safety, tolerability and pharmacokinetics of a single oral dose followed by multiple ascending doses, the combination showed a favourable tolerability and safety profile in healthy volunteers. Currently, Phase II clinical trials have been completed and follow-up observations are planned with the aim of bringing the drug product to the pharmaceutical market.

CONESCO® is a potent, pan-genotypic direct-acting antiviral agent, a new generation NS5A protein inhibitor. The product has demonstrated high efficacy compared to other biotarget inhibitors in difficult-to-treat genotypes and pre-existing NS5A mutations, as well as in patients with HCV/HIV co-infection. The product is expected to be approved by the end of 2024.